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Small molecule inhibitorsPolyoma- and papillomaviruses genome replication is initiated by the binding of large T antigen (LT) and of
E1 and E2, respectively, at the viral origin (ori). Replication of an ori-containing plasmid occurs in cells
transiently expressing these viral proteins and is typically quantiﬁed by Southern blotting or PCR. To
facilitate the study of SV40 and HPV31 DNA replication, we developed cellular assays in which transient
replication of the ori-plasmid is quantiﬁed using a ﬁreﬂy luciferase gene located in cis to the ori. Under
optimized conditions, replication of the SV40 and HPV31 ori-plasmids resulted in a 50- and 150-fold increase
in ﬁreﬂy luciferase levels, respectively. These results were validated using replication-defective mutants of
LT, E1 and E2 and with inhibitors of DNA replication and cell-cycle progression. These quantitative and high-
throughput assays should greatly facilitate the study of SV40 and HPV31 DNA replication and the
identiﬁcation of small-molecule inhibitors of this process.ues de Montréal (IRCM), 110
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Small DNA tumor viruses such as polyoma- and papillomaviruses
rely widely on the host cell DNA replication machinery to replicate
their double-stranded viral genome. Eukaryotic DNA replication is a
complex process that is initiated by several factors including the origin
recognition complex (ORC), Cdt1, Cdc6 and the mini-chromosome
maintenance (MCM) complex, the alleged cellular replicative helicase
(Johnson and O'Donnell, 2005; Masai et al., 2005; Nishitani and
Lygerou, 2002). In contrast, small DNA tumor viruses like polyoma- and
papillomaviruses encode a single initiator protein that performs
multiple functions during viral genome replication. A well-studied
example is the large T antigen (LT) of simian virus 40 (SV40). This
multifunctional initiator protein can successively recognize the viral
origin of replication, assemble into a double hexamer that melts and
unwinds the DNA ahead of the replication fork, and interact with the
host DNA replication factors such as polymeraseα-primase, replication
protein A (RPA) and topoisomerase I (reviewed in (Borowiec et al.,1990; Bullock, 1997)). The analogous protein from papillomavirus, E1,
has similar activities but also requires the viral protein E2 to initiate
viral DNA replication in vivo (reviewed in Hebner and Laimins, 2006).
Papillomavirus E2 is both a replication and transcription factor that
binds with high afﬁnity to sites in the viral origin (Androphy et al.,
1987). As a replication factor, E2 interacts directly with E1 to recruit it
to the origin and favor its assembly into a double hexamer (Blitz and
Laimins, 1991; Lusky et al., 1994; Mohr et al., 1990).
LT and E1 are structurally related members of the helicase
superfamily III (SF3) (Clertant and Seif, 1984; Hickman and Dyda,
2005; Mansky et al., 1997). The C-terminal domains of LT and E1 have
ATPase/helicase activity and are sufﬁcient for oligomerization into
hexamers (Li et al., 2003; Titolo et al., 2000; White et al., 2001). The
central part of both proteins contains an origin-binding domain (OBD)
which recognizes speciﬁc sequences in the origin (McVey et al.,
1989b; Simmons et al., 1990a; Titolo et al., 2003a, 2003b;Wun-Kim et
al., 1993). The OBDs of LT and E1 differ in their primary amino acid
sequence but share a common fold. Interestingly, while the LT OBD
can bind with high-afﬁnity to its target binding site as a monomer, the
E1 OBD needs to dimerize to achieve comparable afﬁnity and
speciﬁcity (Fradet-Turcotte et al., 2007; Titolo et al., 2003a, 2003b).
Crystal structures of the bovine papillomavirus (BPV) and human
papillomavirus (HPV) 18 E1 OBDs have revealed the nature of the
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been shown to impair viral DNA replication (Auster and Joshua-Tor,
2004; Enemark et al., 2002; Schuck and Stenlund, 2005; Titolo et al.,
2003a). Both LT and E1 also differ substantially in their N-terminal
regions, although in either case these contain regulatory elements.
The N-terminal domain of LT contains a unique J-domain required for
replication in vivo (Sullivan and Pipas, 2002), a monopartite nuclear
localization signal (NLS) (Kalderon et al., 1984a, 1984b) and several
phosphorylation sites for different kinases that modulate either the
nuclear import of LT (Rihs et al., 1991) or its assembly into a double
hexamer at the origin (Cegielska et al., 1994; Moareﬁ et al., 1993;
Mohr et al., 1987; Scheidtmann et al., 1984; Schneider and Fanning,
1988; Virshup et al., 1989, 1992; Weisshart et al., 1999). As for the N-
terminal domain of E1, it contains a bi-partite NLS, a Crm1-dependant
nuclear export signal (NES), and a binding site for cyclin A/E-cdk2,
which regulates E1 nucleo-cytoplasmic shuttling by phosphorylation
(Deng et al., 2004; Ma et al., 1999). In addition, this domain of E1
contains a binding site for the cellular protein p80, necessary for
optimal viral DNA replication (Cote-Martin et al., 2008), and a
caspase-3/7 cleavage site required for ampliﬁcation of the viral
genome in differentiated keratinocytes (Moody et al., 2007).
Expression of LT and E1/E2 has been shown to be sufﬁcient to
support replication of a plasmid encompassing their cognate origin in
transiently transfected cells. This type of assay has been used
extensively to deﬁne speciﬁc DNA sequences required for origin–
function in vivo. For SV40, the 64-bp core (nt 5193 to 34) was
identiﬁed as the minimal origin however, replicationwas shown to be
maximal when the adjacent 21-bp repeat region was included
(Bergsma et al., 1982; Lee-Chen and Woodworth-Gutai, 1986). The
middle portion of the core contains four binding sites for LT (5′-
GAGGC-3′), arranged as two pairs of inverted repeats. This middle
region known as site II is ﬂanked on one side by an AT-rich region and
on the other by the early palindrome (EP) (Borowiec et al., 1990;
Bullock et al., 1997; Deb et al., 1987; DeLucia et al., 1983; Parsons et al.,
1990; Tegtmeyer et al., 1983). Similarly, the HPV origin (nt 7721 to
100 for HPV31 (Frattini and Laimins, 1994)) was found to contain fourFig. 1. Principle of the luciferase SV40 DNA replication assay. (A) Schematic representation o
The location of the SV40 origin of replication is represented by a black box with the position
sequence boundaries of the origin are indicated. The locations of the CMV promoter and intr
and Renilla luciferase as well as those of LT are indicated by white boxes. Amino acid bound
assay. A plasmid expressing SV40 LT (pLT) is co-transfected in cells along with a second plasm
gene. A third plasmid expressing Renilla luciferase (pRL) is also transfected as an internal
measured using a dual-luciferase assay, at different times post-transfection.binding sites for E1 (5′-ATTGTT-3′), also arranged as two pairs of
inverted repeats, together with an AT-rich region (Chen and Stenlund,
2001; Holt and Wilson, 1995; Lee et al., 1997; Mendoza et al., 1995;
Sun et al., 1996; Titolo et al., 2003a; Ustav et al., 1991). In addition and
speciﬁc to HPV, the origin of replication contains three binding sites
for the E2 protein (5′-ACCN6GGT-3′) (Androphy et al., 1987).
Replication of an origin-containing plasmid (ori-plasmid) by LT,
or E1/E2, in transiently transfected cells is typically detected by
Southern blotting or PCR (Del Vecchio et al., 1992; Taylor andMorgan,
2003). In these assays, plasmid replication can be detected from either
total or low-molecular weight DNA (i.e. Hirt-extracted DNA) that has
been digested with DpnI to restrict any input transfected ori-plasmid
that failed to replicate and thus retained a methylation pattern
characteristic of bacteria. The numerous steps involved in these
transient DNA replication assays have limited their use for high-
throughput studies such as those involving the characterization of
large number of mutations or the screening of chemical or siRNA
libraries. To overcome this limitation, we have developed facile and
quantitative assays of SV40 and HPV31 DNA replication that rely on a
dual-luciferase readout to measure the amount of replicated origin
DNA directly from transfected cells.
Results and discussion
Development of a novel SV40 DNA replication assay based on a
dual-luciferase readout
To facilitate the study of SV40 DNA replication, we set out to
develop a cellular assay in which transient replication of an origin-
containing plasmid (ori-plasmid) by large T antigen (LT) would result
in increased expression of a ﬁreﬂy luciferase (Fluc) reporter gene
encoded on the same ori-plasmid. A previous study has demonstrated
that LT could boost the expression of several genes, including Fluc,
present in cis of the SV40 origin (de Chasseval and de Villartay, 1992),
thus making it likely that this strategy could be adapted to quantify
SV40 DNA replication. First, we constructed a plasmid containing bothf the three plasmids used in the assay. The name of each plasmid is written on the left.
of the core (grey) and 21 bp-repeat regions (black) enlarged above. The nucleotide (nt)
on are indicated by dark and light grey boxes, respectively. The coding regions of ﬁreﬂy
aries of each protein are indicated below each box. (B) Schematic representation of the
id containing the SV40 origin of replication (pFLORI40) and a ﬁreﬂy luciferase reporter
control to normalize for variations in transfection efﬁciency. Viral DNA replication is
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al., 1981) and a ﬁreﬂy luciferase reporter gene expressed from the
CMV promoter (pFLORI40, Fig. 1A). For LT expression, we used the
previously described plasmid pCMV-T-ag (Campbell et al., 1997)
referred herein as pLT for short, Fig. 1A) in which LT is expressed from
the CMV promoter. A third plasmid encoding Renilla luciferase (Rluc)
expressed from the CMV promoter (pRL, Fig. 1A) was also constructed
as an internal control to correct for differences in transfection
efﬁciencies. In principle, co-transfection of these plasmids into cells
should result in LT-catalyzed replication of the ori-plasmid, which in
turn should increase speciﬁcally the expression of ﬁreﬂy luciferase but
not that of Renilla (Fig. 1B). To verify this assumption, we co-
transfected the pFLORI40 (2.5 ng), pLT (12.5 ng) and pRL (0.5 ng)
plasmids in 5×104 C33A cervical carcinoma cells, in duplicates, and
measured the amounts of ﬁreﬂy and Renilla luciferase activities at
different time points post-transfection (Fig. 2A). As a negative control,
pLT was co-transfected with a ﬁreﬂy luciferase vector lacking the
SV40 origin (Ori−). C33A cells were used in this study because they
support both SV40 and HPV DNA replication and allow a direct
comparison of both DNA replication assays and inhibitors thereof. TheFig. 2. Dependence of the SV40 DNA replication assay on time and expression of T
antigen. (A) Replication of the SV40 origin-containing plasmid (Ori+), or of a similar
plasmid lacking the origin (Ori−), as a function of time post-transfection (in hours).
C33A cells were transfected with 12.5 ng of pLT together with 2.5 ng of pFLORI40 and
0.5 ng of RL, and luciferase activities measured at the indicated time points post-
transfection. (B) Western blot showing the expression of LT at different time points
post-transfection. Tubulin was used as a loading control. Note that the time-dependent
increase in tubulin levels reﬂects the fact that cells continued to proliferate over the
course of this 5-day assay. (C) Replication of the SV40 origin-containing plasmid by
increasing amounts of pLT (12.5, 25, 50 and 100 ng). Cells transfected without the LT
expression vector (−) were used as a negative control. Replication by a gradient of LT
was determined at 24, 48, 72 and 96 h, as indicated.results from these experiments are presented in Fig. 2A as the ratio of
ﬁreﬂy (Fluc) to Renilla (Rluc) luciferase activity measured 24, 48, 72,
96 and 120 h post-transfection. High Fluc/Rluc ratios were obtained
only from cells transfected with the origin-containing plasmid (Ori+)
and not from those transfected with the negative control (Ori−). The
Fluc/Rluc ratios gradually increased at 24 and 48 h and reached a
maximumat 72 h. Consistentwith this observation, we determined by
Western blotting that the levels of LT reached a maximum at 48 h
post-transfection and then diminished at later time points (96 and
120 h; Fig. 2B). During the development of this assay, we noticed that
the maximal level of SV40 DNA replication was occasionally reached
at 96 rather than 72 h post-transfection (see Fig. 2C as an example).
However, because the assay always remained linear up to 72 h, we
chose this time point for all subsequent experiments. Collectively,
these results indicate that the high Fluc/Rluc ratios are dependent on
the presence of the SV40 origin on the Fluc plasmid and establish a
correlation between the increase in Fluc/Rluc values and the
expression levels of LT. From this data, we surmised that the high
Fluc/Rluc ratios were the result of LT-catalyzed replication of the ori-
plasmid.
Dependence of the assay on large T antigen expression
To more rigorously examine the dependence of the assay on the
expression levels of LT, we transfected cells with a gradient of pLT
(12.5, 25, 50 and 100 ng) while keeping the amount of the other
two plasmids constant (Fig. 2C). Cells not transfected with pLT were
used as a negative control. These experiments were performed in
duplicates and luciferase activities measured at different time points
post-transfection. These studies revealed that the Fluc/Rluc ratios
were proportional to the quantity of transfected LT expression vector
for the three lowest amounts (12.5, 25 and 50 ng) but then reached a
plateau. Throughout the development of this assay, we observed that
the Fluc levels could be increased by as much as 50-fold by LT (Fig. 2).
As expected, the Rluc levels remained relatively constant when 50 ng
or less of pLT vector was used (data not shown). Altogether, these
results indicate that the Fluc/Rluc ratio is proportional to the
expression levels of LT and further support the notion that increases
of the Fluc/Rluc ratio occur as a consequence of ori-plasmid
replication.
Validation of the assay with mutant large T antigens
To validate that the Fluc/Rluc ratio increases as a function of
plasmid replication, we tested in the luciferase assay several LT
mutant proteins whose molecular defects have been previously
reported in the literature. Each mutant was tested in three different
amounts (2.5, 6.25, and 12.5 ng of pLT), in duplicates and on several
days. A representative experiment is shown in Fig. 3A. LTmutants that
were previously shown to be defective for double hexamer assembly
(T124A) (McVey et al., 1989a, 1993, 1996; Moareﬁ et al., 1993;
Schneider and Fanning, 1988; Weisshart et al., 1999) or DNA binding
(N153S) (Simmons et al., 1990b, 1993) were inactive in our luciferase
assay, as anticipated. We next tested the effect of the T199A
substitution in the OBD, which was previously shown to affect
transient DNA replication when combined with other substitutions
(P200L and S206F or T182I and H192T) (Welsh et al., 1986) but
was never tested on its own. We found that T199A LT retained
approximately 20% activity relative to the wild-type protein. Fluc/
Rluc values were also reduced to background levels by amino acid
substitutions that abrogate the ATPase activity (K432A) or disrupt the
essential β-hairpin (K512A/H513A and H513A alone) (Kumar et al.,
2007) of LT. As a control, we veriﬁed by Western blotting that the
different LT mutants were expressed at comparable levels (Fig. 3B).
Together, these ﬁndings indicate that the DNA binding and helicase
activities of LT are required to achieve high Fluc/Rluc ratios.
Fig. 3. Validation of the SV40 DNA replication assay using T antigen mutants. (A)
Replication activity of mutant T antigens in C33A cells. Each mutant was tested in three
different amounts of pLT (2.5, 6.25 and 12.5 ng). Cells transfected without LT expression
vectors (No LT) was used as a negative control. Replication activity is reported as a
percentage (%) of the Fluc/Rluc ratio obtained with 12.5 ng of the LT wild-type, which
was set at 100. (B) Western blot showing the expression of the different T antigen
mutant proteins. Tubulin was used as a loading control.
Fig. 4. Principle of the luciferase-based HPV31 DNA replication assay. (A) Schematic
representation of the three HPV plasmids used in the luciferase assay. The name of each
plasmid is written on the left. The location of the CMV promoter and 3F epitope are
indicated as dark and light grey boxes, respectively. The coding regions of ﬁreﬂy and
Renilla luciferase as well as those of codon-optimized (co) E1 and E2 are indicated by
white boxes. Amino acid boundaries are indicated below each box. The location (black
box) and nucleotide boundaries of the HPV31 origin of replication are indicated with
the position of E1 (black) and E2 (grey) binding sites enlarged above. (B) DNA
replication activities measured in C33A cells transfected with the indicated amount of
E1 and E2 expression vectors together with 2.5 ng of pFLORI31 and 0.5 ng of pRL. DNA
replication activities are expressed as Fluc/Rluc ratios and were determined at 24, 48,
72, 96 and 120 h post-transfection, as indicated. (C) Western blots showing the
expression of E1 and E2 at different time points post-transfection. Tubulin was used as a
loading control. Note that the time-dependent increase in tubulin levels reﬂects the fact
that cells continued to proliferate over the course of this 5-day assay.
68 A. Fradet-Turcotte et al. / Virology 399 (2010) 65–76Development of a luciferase HPV31 DNA replication assay
Based on our success with SV40, we set out to establish a similar
assay for HPV, which uses two proteins, E1 and E2, rather than a single
one to initiate viral DNA replication. To do so, we constructed a
plasmid containing the HPV31 origin of replication (nucleotides
7721–100) (Frattini and Laimins, 1994) and a ﬁreﬂy luciferase
reporter gene expressed from the CMV promoter (pFLORI31,
Fig. 4A). We also constructed expression vectors for HPV31 E1 and
E2 tagged at their N-terminus with a triple-Flag (3F) epitope (p31E1
and p31E2, Fig. 4A). In these vectors, the coding sequences of E1 and
E2 have been codon-optimized for expression in human cells and are
transcribed from the CMV promoter. These three plasmids (2.5 ng
pFLORI31, 10 ng p31E1, 10 ng p31E2), along with the pRL control
plasmid described above (0.5 ng), were co-transfected, in duplicates,
in 5×104 C33A cells and the amount of ﬁreﬂy and Renilla luciferase
activities measured 24, 48, 72, 96 and 120 h post-transfection. As
negative controls, cells were also transfected without E1, E2 or both.
The results from these experiments are presented in Fig. 4B as the
ratio of ﬁreﬂy to Renilla luciferase activities measured at each time
point. High Fluc/Rluc ratios were obtained only from cells expressing
both E1 and E2 and were readily detectable as early as 24 h post-
transfection. Maximum DNA replication was reached at 72 h,
consistent with the fact that E1 and E2 expression was maximal at
24 and 48 h post-transfection and then declined (Fig. 4C).
To further ascertain that the Fluc/Rluc ratios were dependent on
expression of E1 and E2, we titrated the amount of p31E1 or p31E2
(from 0.01 ng to 25 ng) while keeping the amounts of the other three
plasmids constant (Fig. 5). These experiments, performed in octupli-
cates, revealed that the Fluc levels increased proportionally to the
amount of E1 and E2, in contrast to the Rluc levels which varied by
two-fold or less (Figs. 5B and C). At high concentrations of E1 and E2,
replication of the ori-plasmid (i.e. Fluc/Rluc ratio) could be increased
by as much as 150-fold (Fig. 5A). Importantly, we also demonstratedthat the assay signal measured at the highest quantity of E1 and E2
(25 ng each) was dependent on the presence of the origin on the Fluc
reporter plasmid (No ori, Fig. 5). Collectively, these results indicate
that the Fluc/Rluc ratio is a good indicator of the amount of ori-
plasmid replicated by E1 and E2.
Validation of the luciferase HPV31 DNA replication assay with E1 and E2
mutant proteins
To validate the luciferase assay, we tested the effect of amino acid
substitutions in E1 and E2 that were previously characterized in a
conventional (i.e. Southern-based) transient DNA replication assay.
(i) E1 mutants
Each mutant was tested at three different amounts (2.5, 5 and
10 ng of p31E1 together with 10 ng of p31E2) in duplicates and
Fig. 5. Dependence of the HPV31 DNA replication assay on E1 and E2. (A) Replication of
the HPV31 origin-containing plasmid in C33A cells transfected with increasing amounts
of E1 (white bars) and E2 (black bars) expression vectors (2-fold increments ranging
from 0.01 to 25 ng) as described in the text. Cells transfected without the E1 or E2
expression vector (−) were used as negative controls. Cells transfected without E1 and
E2 expression vectors (No E1/E2) as well as cells transfected with E1 and E2 but with a
plasmid lacking the origin (No ori) were used as controls and are represented as grey
bars. (B) and (C) Fireﬂy and Renilla luciferase values (reported as relative light units,
RLU) that were used to calculate the ratios presented in (A).
Fig. 6. Validation of the HPV31 DNA replication assay using E1 mutants. (A) DNA
replication activities of the indicated E1 mutants were tested using three different
amounts of expression vector (2.5, 5 and 10 ng). Cells transfected without E1
expression vector (No E1) was used as a negative control. Replication activity is
reported as a percentage (%) of the Fluc/Rluc ratio obtained with 10 ng of the E1 wild-
type. (B) Anti-FlagWestern blot showing the expression of E1 mutant proteins. Tubulin
was used as a loading control.
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As can be seen, E1 mutants that were previously shown to be
defective for DNA binding (K265A/R267A) (Titolo et al., 2000,
2003b) or oligomerization and ATPase activity (F372A, K463A)
(Titolo et al., 2000; White et al., 2001) were also defective in the
luciferase assay. Furthermore, E1 mutants that are defective for
interaction with the cellular protein p80 (W17A/F18A, V20A/E21A
and V23A/I24A) showed a reduction of approximately 60% in
replication activity in the luciferase assay, similarly to what we
determined previously in a conventional assay (Cote-Martin et al.,
2008). As controls, we veriﬁed that the different E1 mutants were
expressed to comparable levels by Western blotting against the 3F
epitope (Fig. 6B).We and others previously reported that the OBD from HPV11, 18
and BPV E1 can dimerize in vitro (Auster and Joshua-Tor, 2004;
Enemark et al., 2002; Schuck and Stenlund, 2005; Titolo et al., 2003a).
Furthermore, we have shown for HPV11 that a dimerization-defective
E1 mutant was capable of only low levels of replication (Titolo et al.,
2003a). To determine if our assay is sensitive enough to detect low
levels of replication and to assess the contribution of dimerization to
transient DNA replication, we characterized an HPV31 E1 mutant
carrying the amino acid substitution G230R that should prevent
dimerization. G230 forms part of the OBD dimer interface and its
change to arginine, a much bulkier and charged amino acid, is
expected to prevent dimerization by steric hindrance and by inducing
charge repulsion between adjacent OBDs. We ﬁrst veriﬁed this
assumption by testing the effect of the G230R substitution on the
ability of the puriﬁed HPV31 OBD to bind and dimerize on DNA
(Fig. 7A), using an in vitro DNA binding assay based on ﬂuorescence
polarization which we previously described (Fradet-Turcotte et al.,
2007; Titolo et al., 2003a). Speciﬁcally, we measured the afﬁnities of
the wild-type and G230R OBDs for a ﬂuorescein-labeled probe
containing two E1 binding sites placed in an inverted orientation
and separated by 3 bp (2 E1BS probe). We previously determined that
the HPV11 and BPV E1 OBDs can bind and dimerize efﬁciently on this
combination of siteswhich is found twice in the viral origin (Titolo et al.,
2003a). As expected, the G230R mutant bound more weakly to this
probe with a 7-fold lower afﬁnity (KD=281±12 nM) than the wild-
typeOBD (KD=40±3nM) (Fig. 7B).We thenmeasured the afﬁnities of
both OBDs for a probe containing 2 E1BS spaced by 5 bp, instead of 3, to
preclude dimerization (2+2 E1BS probe). Binding to this probe was
found to be similar for both the wild-type (KD=134±8 nM) and
mutantOBD (KD=184±5nM) (Fig. 7C), thus indicating that theG230R
substitution only affects dimerization andnot the interaction of theOBD
with a single binding site. Finally,we conﬁrmed that bindingof thewild-
Fig. 7. Characterization of a dimerization-defective HPV31 E1mutant. (A) Coomassie-stained SDS-PAGE showing the puriﬁed wild-type and G230R E1 OBDs. 3 μg of each protein was
loaded on the gel. (B-D) Fluorescence polarization DNA binding assays. Binding isotherms were performed with increasing concentrations of wild-type (ﬁlled squares) or G230R
(open squares) OBD and 10 nM of ﬂuorescent DNA probe either lacking (No E1BS probe (D)) or containing two E1 binding sites spaced by 3 bp (2 E1BS probe (B)) or 5 bp (2+2 E1BS
probe (C)). Only a spacing of 3 bp allows dimerization of the OBD. Each binding isotherm was performed in triplicate. (E) DNA replication activities of wild-type and G230R E1 were
tested using three different amounts of expression vector, as described in the text. (F) Anti-Flag Western blot showing the expression of E1 proteins. Tubulin was used as a loading
control.
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only weakly to a probe lacking a speciﬁc binding site (No E1BS probe,
Fig. 7D). Next, we tested the effect of the G230R substitution on the
ability of full-lengthHPV31 E1 to support transientHPVDNA replication
in vivo using the luciferase assay. The G230R E1 mutant was severely
defective in supporting viral DNA replication, showing a 8-fold
reduction in activity compared to wild-type E1 (Fig. 7E). This defect
was not due to a reduced expression of the mutant protein as it was
expressed to comparable levels as wild-type E1, as determined by
Western blotting (Fig. 7F). These results suggested that dimerization of
the OBD enhances DNA binding in vitro and origin-replication in vivo to
similar extents, namely by 7- and 8-fold respectively. These results
highlight the critical role played by theOBDdimer interface in HPVDNA
replication and indicate that the assay canmeasure accurately even low-
levels of replication.
(ii) E2 mutants
E2 mutants were tested essentially as described above for E1 and
using 1.0, 2.5 and 5.0 ng of p31E2 together with 25 ng of p31E1. A
representative experiment is shown in Fig. 8A. The I73L substitutionin the E2 TAD that affects transactivation but not DNA replication had
no effect in the luciferase assay (Baxter et al., 2005; Brokaw et al.,
1996; Cooper et al., 1998; Ferguson and Botchan, 1996; Sakai et al.,
1996; Stubenrauch et al., 1998). This result is in complete agreement
with a previous study on HPV31 E2 that showed little to no effect of
the I73L substitution on transient DNA replication measured with a
Southern-based assay (Stubenrauch et al., 1998). In contrast, the E39A
and E39Q substitutions that affect E1-binding signiﬁcantly reduced
replication (Abbate et al., 2004; Ferguson and Botchan, 1996; Harris
and Botchan, 1999; Sakai et al., 1996; Stubenrauch et al., 1998).
Interestingly, low levels of replication were obtained with the E39
mutants suggesting that they are not completely defective for
interaction with E1. A similar ﬁnding was previously reported for
codon-optimized HPV11 E2 E39A (Wang et al., 2003). As controls, we
veriﬁed that the different E2 mutants were expressed to comparable
levels by Western blotting against the 3F epitope (Fig. 8B).
Interestingly, we repeatedly observed that the E2 mutant E39A was
less stable than the wild-type protein.
Altogether, the results obtained with E1 and E2 mutants described
above provide additional evidence that the Fluc/Rluc ratio reﬂects
Fig. 8. Validation of the HPV31 DNA replication assay using E2 mutants. (A) DNA
replication activities of the indicated E2 mutants were tested using three different
amounts of expression vector (1, 2.5 and 5 ng). Cells transfected without E2 expression
vector (No E2) was used as a negative control. Replication activity is reported as a
percentage (%) of the Fluc/Rluc ratio obtained with 5 ng of E2 wild-type. (B) Anti-Flag
Western blot showing the expression of E2 mutant proteins. Tubulin was used as a
loading control.
Fig. 9. Correlation between ori-plasmid replication and ﬁreﬂy luciferase expression. (A)
Levels of SV40 plasmid replication measured by quantitative real-time PCR (qPCR) or
determined by measuring levels of ﬁreﬂy luciferase activity. C33A cells were
transfected with the pFLORI40 plasmid and the LT expression vector (+LT). As
controls, cells were transfected without the LT expression vector (No LT) or with a
similar plasmid lacking the ori (No ori). The amounts of DNA replication measured by
qPCR are reported in pg of DpnI-resistant plasmid per mg of total genomic DNA. Fireﬂy
luciferase (Fluc) activity is reported in relative light units (RLU). (B) A similar analysis
was performed for HPV31 DNA replication with the exception that cells were
transfected with the pFLORI31 plasmid, or a similar plasmid lacking the ori (No ori),
and with expression vectors for E1 and E2, as indicated.
71A. Fradet-Turcotte et al. / Virology 399 (2010) 65–76replication of the ori-plasmid. Furthermore, they indicate that the
luciferase DNA replication assay behaves similarly as the conventional
assay and is well suited for measuring accurately even low levels of
DNA replication.
Luciferase activity increases as a function of ori-plasmid replication
The experiments presented above functionally validated the use
of the luciferase readout to monitor SV40 and HPV31 DNA replication
but did not directly correlate the increase in luciferase activity with
replication of the ori-plasmid. To establish this correlation, we
measured, in the same experiment, the levels of ﬁreﬂy luciferase
activity originating from the ori-plasmid and the amount of
replication of this plasmid by quantitative real-time PCR (qPCR).
For the SV40 assay, C33A cells were transfected essentially as
described above with the pFLORI40 plasmid and the LT expression
vector (+LT). Cells transfected with the Fluc plasmid lacking the ori
(pCI-Fluc; No ori), or with pFLORI40 but without the LT expression
vector (No LT), were used as controls. 72 h post-transfection, both
the levels of Fluc activity and the amount of replicated ori-plasmid
were measured in parallel. Plasmid replication was determined by
ampliﬁcation of a portion of the Fluc open-reading frame from DpnI-
digested total genomic DNA and the amount of ampliﬁed plasmid
quantiﬁed using a 7-point standard curve (as described in Materials
and methods). Fig. 9A (left panel) shows that high levels of
replicated ori-plasmid were detected only in cells expressing LT
and not in control cells, as expected. Importantly, these results
paralleled those obtained by measuring the levels of Fluc activity by
luminescence (Fig. 9A, right panel). Thus, only cells that contain
signiﬁcant amounts of replicated ori-plasmid express high levels of
ﬁreﬂy luciferase activity. We also performed a similar analysis for the
HPV31 assay. Once again, the levels of replicated (DpnI-resistant)
HPV31 ori-plasmid were detected in high amounts only in cells
expressing both E1 and E2 (+E1/+E2) (Fig. 9B, left panel). These
same cells also expressed high levels of ﬁreﬂy luciferase (Fig. 9B,
right panel). Collectively, the results presented above provide direct
evidence that the levels of ﬁreﬂy luciferase activity are increased as afunction of ori-plasmid replication, in both the SV40 and HPV31
assays.
Inhibition of SV40 and HPV DNA replication by the cytidine analogue
gemcitabine
To further validate the SV40 and HPV31 transient DNA replication
assays and assess their potential for testing small molecule inhibitors,
we investigated the effect of a known DNA replication inhibitor,
gemcitabine, a cytidine analogue currently used for the treatment of
several cancers (Fig. 10A) (Jiang et al., 2000;Mini et al., 2006).We ﬁrst
determined that both assays are tolerant to 0.1% DMSO, which was
used as a vehicle in our study (data not shown). Increasing
concentrations of gemcitabine (1.56 to 50 nM) were then tested. In
order to minimize any potential cytotoxic effects of the drug,
gemcitabine was added to transfected cells 24 h prior to measuring
luciferase activities. As can be seen in Fig. 10B, gemcitabine inhibited
both SV40 and HPV DNA replication in a dose-dependent manner
with an IC50 of approximately 50 and ∼12.5 nM, respectively.
Gemcitabine decreased expression of the Fluc signal (Fig. 10C) and
had no effect on the levels of Rluc (Fig. 10D), suggesting that it
speciﬁcally affected viral DNA replication. To conﬁrm this suggestion
Fig. 10. Validation of the SV40 and HPV31 assays using the DNA replication inhibitor
gemcitabine. (A) Structure of gemcitabine. (B) Replication activity measured in cells
treated with increasing concentrations of gemcitabine (2-fold increments ranging from
1.56 to 50 nM) or treated with DMSO as a vehicle control (−). Replication activity is
reported as a percentage (%) of the Fluc/Rluc ratio obtained in presence of DMSO only.
(C and D) Fireﬂy and Renilla luciferase values, reported as a percentage of the values
obtained without gemcitabine (DMSO only), that were used to calculate the replication
activity levels shown in (B). (E) Effect of gemcitabine on expression of CMV-Fluc in the
absence of plasmid replication (No replication) is reported as a percentage (%) of the
value obtained in absence of gemcitabine (DMSO only).
Table 1
Activity of selected cell-cycle inhibitors on viral DNA replication. Inhibitors were tested
in presence and absence of viral DNA replication as described in the text. DNA pol: DNA
polymerases, RR: Ribonucleotide reductase. ⁎ Inhibitors were tested for their effect on
expression of the ﬁreﬂy luciferase reporter gene in absence of viral DNA replication,
using a 40-fold excess of Fluc ori-plasmid as described in the text.
Inhibitor Cellular
target
Cell cycle
phase
IC50 (μM)
SV40 HPV31 Fluc expression ⁎
(no replication)
Gemcitabine DNA
pol/RR
S 0.05 0.012 N0.05
Hydroxyurea RR S 1000 250 N2000
Mimosine Unknown G1/S 500 250 N500
Geldanamycin HSP90 G1 0.025 0.05 N0.2
17-AAG HSP90 G1 0.5 0.5 N2.0
Lactacystin Proteasome G1-G2/M 1.25 1.25 N10
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the Fluc reporter gene, we measured its activity in absence of viral
DNA replication (i.e. in absence of viral proteins). Forty-fold higheramounts of the ori-plasmid pFLORI31 were transfected in these
experiments (without LT, E1 and E2 but together with pRL; No
replication) in order to mimic the levels of ﬁreﬂy luciferase activity
originating from a replicated ori-plasmid. Indeed, whereas SV40 and
HPV DNA replication typically results in a ﬁreﬂy luciferase signal of 1
and 3×106 RLU, respectively, transfection of cells with a 40-fold
excess of ori-plasmid (in absence of replication proteins) typically
yields 2×106 RLU. Under these non-replicating conditions, gemcita-
bine had no effect on ﬁreﬂy luciferase expression, further demon-
strating that it speciﬁcally inhibits LT- and E1/E2-dependent DNA
replication and not expression of the Fluc reporter gene (Fig. 10E). As
an example of a compound that affects DNA replication indirectly, we
used the DNA intercalating agent Actinomycin D which blocks
transcription. As expected, Actinomycin D affected the levels of both
ﬁreﬂy and Renilla luciferase (data not shown). Thus, Renilla luciferase
can also be used as a control to detect compounds that affect
transcription from the CMV promoter. This is a particularly important
control given that the CMV promoter is also used to drive expression
of LT, E1 and E2. More generally, these data indicated that the
luciferase assay is suitable for testing small molecule inhibitors and
accurately measure their potency (IC50 determination).
Inhibition of SV40 and HPV DNA replication by chemical inhibitors of
the cell cycle
SV40 and HPV DNA replication occurs during the S-phase of the
cell cycle. We therefore anticipated that our assays would be sensitive
to chemical inhibitors that cause cell cycle arrest and/or perturb S-
phase. To verify this prediction, we measured the activity of several
different inhibitors in the luciferase SV40 and HPV DNA replication
assays (Table 1). As a control, they were also tested for their effect on
CMV-Fluc expression in the absence of viral replication proteins
(Table 1, Fluc expression (no replication)), as described above for
gemcitabine. First, we examined the effect of hydroxyurea (HU), an
inhibitor of ribonucleotide reductase that prevents S-phase progres-
sion (reviewed in (Krek and DeCaprio, 1995)). As anticipated, HU
inhibited viral DNA replication (IC50=1000 and 250 μM for SV40 and
HPV, respectively) with little effect on expression of CMV-Fluc
(IC50N2000 μM). A similar pattern was found for mimosine, a
commonly used inhibitor that blocks cells in late G1 near the G1/S-
phase transition (IC50=500 and 250 μM for SV40 and HPV) (Gilbert et
al., 1995; Hughes and Cook, 1996; Krek and DeCaprio, 1995; Krude,
1999; Wang et al., 2000; Watson et al., 1991). We also tested the
activity of two HSP90 inhibitors, geldanamycin and its derivative 17-
AAG, which have been reported to block cell-cycle progression in G1
(Bedin et al., 2004; Munster et al., 2001; Srethapakdi et al., 2000). We
found that both compounds could prevent viral DNA replication
(geldanamycin: IC50= 0.025 and 0.05 μM for SV40 and HPV; 17-AAG:
IC50= 0.5 μM for both SV40 and HPV), with less of an effect on
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proteasome inhibitor lactacystin, which was also reported to block S-
phase entry by arresting cells either in G1 or G2/M phase (Katagiri et
al., 1995; Keezer and Gilbert, 2002). Like the two HSP90 inhibitors,
lactacystin inhibited viral DNA replication (IC50=1.25 μM for both
SV40 and HPV). Because the cell cycle inhibitory effect of geldana-
mycin and lactacystin is not as well documented in the literature as
that of HU andmimosine, we veriﬁed that both compounds prevented
S-phase entry under our assay conditions. Speciﬁcally, we determined
by confocal ﬂuorescence microscopy that geldanamycin and lacta-
cystin could prevent the accumulation of PCNA (as a fusion to RFP)
into nuclear foci characteristics of cells in S-phase (Supplementary
Fig. 1) (Gorisch et al., 2008; Schermelleh et al., 2007; Sporbert et al.,
2005). Collectively, these studies provided evidence that our
luciferase assays are indeed measuring SV40 and HPV31 DNA
replication that occurs during S-phase.
Concluding remarks
In this study, we described the development of novel assays to
monitor SV40 and HPV31 DNA replication in transiently transfected
cells. We established that replication of the ori-plasmid during
S-phase results in increased luciferase expression and conﬁrmed
these ﬁndings using known replication-defective mutants of LT, E1
and E2, as well with small molecule inhibitors of DNA replication and
cell-cycle progression. These assays offer several unique advantages
over traditional Southern- or PCR-based assays. The major ones are
probably that they require very few steps, do not rely on radio-
activity and are quantitative, thus making them suitable for high-
throughput studies. For example, these assays would be ideal to
screen chemical libraries for new antiviral compounds or siRNA
libraries to systematically identify host factors involved in viral DNA
replication. In this respect, we have shown that these assays are
highly suitable for chemical inhibitor testing and IC50 determination
in 96-well plates. An important feature of these assays is the use of
Renilla luciferase as an internal control to correct for variations in
transfection efﬁciency and cell viability. Furthermore, since Renilla
luciferase is expressed from the CMV promoter, like the ﬁreﬂy
luciferase reporter and the viral replication proteins LT, E1 and E2, it
can be used to detect inhibitors which indirectly affect viral DNA
replication by changing expression of the viral proteins. Finally, the
methods described in this manuscript should be directly applicable
to other polyoma- and papillomaviruses. It is anticipated that these
assays will facilitate the analysis of how different DNA tumor viruses
replicate their genomes and the roles that replication factors play in
this process.
Materials and methods
Plasmid constructions and mutagenesis
The plasmid to express SV40 Large T antigen, pCMV-T-ag (referred
herein as pLT for short), has been described previously (Campbell
et al., 1997). Plasmid pFLORI40, which contains a ﬁreﬂy luciferase
gene under the control of the CMV promoter and the SV40 origin of
replication, was constructed in two steps. First, the ﬁreﬂy luciferase
(Fluc) gene from pGL3-basic (Promega) was inserted between the
XhoI and XbaI restriction sites of pCI (Promega) to create pCI-Fluc.
Second, a PCR fragment spanning the SV40 origin of replication
(nucleotides 5094–161 of the complete genome according to the
numbering system of Buchman et al. (1981), NCBI Reference
Sequence: NC_001669.1) was inserted into the DraIII site of pCI-Fluc
to generate pFLORI40. Primers used for the ampliﬁcation of the SV40
origin were designed to encode DraIII restriction sites and were of the
following sequence: 5′-CGCATCACGTAGTGCCTCCCCAGCAGGC-3′ and
5′-CGCATCACTACGTGCCACTCCTTTCAAGACC-3′. The plasmids to ex-press HPV31 E1 and E2 were obtained by inserting the codon-
optimized genes, synthesized commercially (GenScript Corp.), be-
tween the BamHI–EcoRI sites (E1) or BamHI-HindIII sites (E2) of
pCMV-3Tag-1a (Stratagene) to create in frame fusions with the triple-
Flag (3F) epitope. The HPV origin-containing plasmid (pFLORI31) was
constructed as described above for pFLORI40 with the difference that
the PCR fragment spanning the HPV31 origin of replication (nucleo-
tides 7721–100 of the complete genome according to numbering
scheme of Frattini and Laimins, 1994 (Frattini and Laimins, 1994) NCBI
Reference Sequence: J04353.1) was inserted into the NgoMIV site of
pCI-Fluc to create pFLORI31. Primers used for the ampliﬁcation of
the HPV31 origin were designed to encode NgoMIV restriction sites,
and were of the following sequence: 5′-CGCATGCCGGCAAACTGC-
TTTTAGGCACATATTTTG-3′ and 5′-CGCATGCCGGCGTAGGTTTGCA-
CAAAATACTATGTG-3′. Plasmid pRL coding for Renilla luciferase
(Rluc) was constructed by inserting a PCR fragment encoding Rluc
between the SalI and NotI sites of pCI. The following primers were
used: 5′-CCACCGTCGACGCCACCATGACCAGCAAGGTGTACG-3′ and
5′-CCCGCGGCCGCTTATCTAGATCCGGTGGATCC-3′. Site-directed mu-
tagenesis was performed using the QuickChange mutagenesis kit
(Stratagene). All DNA constructs were veriﬁed by sequencing. Further
details on their construction will be provided upon request.
Cell culture and transfections
C33A human cervical carcinoma cells were grown in Dulbecco's
modiﬁed Eagle's medium (DMEM), supplemented with 10% fetal
bovine serum, 0.5 IU/ml of penicillin, 50 μg/ml streptomycin, and
2 mM L-glutamine. Transfections were performed using the
Lipofectamine 2000 reagent according to the manufacturer's recom-
mendations (Invitrogen).
Luciferase DNA replication assay
C33A cells were plated 20 h before transfection in white ﬂat-
bottom 96-well plates (Corning) at a density of 25000 cells/well. The
total quantity of plasmid DNA transfected was adjusted to 100 ngwith
the empty vector (pCI) for the SV40 assay, and with (pCMV-3Tag-1a)
for the HPV assay, as carrier DNA. For all experiments, 2.5 ng of the
origin-containing plasmid pFLORI40 (Fluc) or pFLORI31 (Fluc) and
0.5 ng of pRL (Rluc) were transfected, along with the indicated
amount of pLT or pE1 and pE2, respectively. The culture medium was
changed 4 h post-transfection. Fresh media was added and ﬁreﬂy and
Renilla luciferase activities were measured using the Dual-Glo
Luciferase assay system (Promega) 24 to 120 h post-transfection.
Fluorescence polarization DNA binding assay
The wild-type and G230R HPV31 E1 OBDs were expressed as
fusions to GST and puriﬁed from bacteria as described previously
(Fradet-Turcotte et al., 2007). The duplex DNA probes were prepared
by annealing a ﬂuorescein-labeled oligonucleotide to its complemen-
tary oligonucleotide as described previously (Titolo et al., 2003a).
150 μl binding reactions were assembled in 96-well HTRF plates
(Packard) using 10 nM ﬂuorescein-labeled probe and the indicated
concentrations of protein in the following buffer: 20mMTris (pH 7.6),
50mMNaCl, 0.01% NP-40, and 1mMDTT. Fluorescence readings were
recorded and KD values calculated as previously described (Fradet-
Turcotte et al., 2007; Titolo et al., 2003a).
Quantitative PCR (qPCR) analysis
Approximately 1.2×106 C33A cells were transfected in 6-well
plates with 60 ng of pFLORI40 and 300 ng of pLT for the SV40 DNA
replication assay or with 60 ng pFLORI31, 240 ng of p31E1 and 240 ng
of p31E2 for the HPV31 DNA replication assay. In both assays, 12 ng of
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luciferase-based assay. The total quantity of plasmid DNA transfected
was adjusted to 2400 ng with empty vector, either pCI for the SV40
assay or pCMV-3Tag-1a for the HPV31 assay, as carrier DNA. Total
genomic DNA was extracted 72 h post-transfection using the DNeasy
kit from Qiagen. This method of DNA isolation was found to yield
more reproducible results than the commonly used Hirt-extraction
protocol (Taylor andMorgan, 2003) (data not shown). Tomeasure the
amount of replicated pFLORI31 or pFLORI40, 25 μl of total genomic
DNA was digested with 10 units of DpnI (New England Biolabs) for
16 h in a ﬁnal volume of 30 μl. The digested DNA samples were then
incubated for 30 min with 100 units of Exonuclease III (New England
Biolabs) and the enzyme was heat inactivated at the end of the
reaction by incubation at 70 °C for 30 min. The primers used to
amplify an 80 bp-portion of the ﬁreﬂy luciferase gene present on the
pFLORI40 (SV40 ori), pFLORI31 (HPV31 ori) or pCI-Fluc (No ori)
plasmids as well as the probe used to detect the amplicon were
synthesized according to unpublished sequences validated by Dr Iain
Morgan (personal communication). These primers amplify a portion
of Fluc that encompasses two DpnI sites and the probe, which is
labeled with FAM and TAMRA at its 5′ and 3′ end, respectively,
hybridizes to a region that overlaps these two DpnI sites. Real-time
qPCR was performed using 4.5 μl of a 5-fold dilution of digested
genomic DNA, 900 nM of primers and 125 nM of probe in “PerfeCTa™
qPCR SuperMix, UNG, Low ROX” buffer (Quanta Biosciences, this
buffer contains: dATP, dCTP, dGTP and dUTP; MgCl2; AccuStart Taq
DNA Polymerase; UNG; ROX reference dye and stabilizers). PCR
reactions were performed on a real-time PCR system (Mx3005P,
Stratagene) using the following PCR ampliﬁcation conditions: 95 °C
for 15 s and 60 °C for 1 min, for 40 cycles. Quantiﬁcation was per-
formed using a 7-point standard curve of pCI-Fluc plasmid ranging
from 104 to 10−2 pg (10-fold serial dilutions). Plasmid quantities
were reported in pg per mg of total genomic DNA extracted. Each
value is the average of at least three replicates.
Inhibitors
C33A cells were plated and transfected essentially as described for
the luciferase DNA replication assay. For SV40, a constant amount of
12.5 ng of pLT was used in each well along with 2.5 ng of pFLORI40
and 0.5 ng of pRL plasmid. The culture mediumwas replaced 4 h post-
transfection with fresh medium. The inhibitors were added 48 h post-
transfection by changing the culture medium with fresh medium
containing the inhibitor or vehicle alone (0.1% DMSO). Finally, fresh
media was added again 72 h post-transfection and ﬁreﬂy and Renilla
luciferase activities measured using the Dual-Glo Luciferase assay
system (Promega). For HPV, the assay was essentially the same, but
the inhibitors were added directly to the assay 4 h post-transfection
and the ﬁreﬂy and Renilla luciferase activities were measured 24 h
post-transfection. For both assays, two-fold serial dilutions of each
inhibitor were assayed starting at a maximal concentration of 50 nM
for gemcitabine, 2 mM for hydroxyurea, 500 μM for mimosine, 0.2 μM
for geldanamycin, 2 μM for 17-AAG and 10 μM for lactacystin.
Lactacystin was purchased from Cayman (Cat: 70980), geldanamycin
and 17-AAG from BIOMOL international (Cat: EI-280 and EI-308,
respectively) and both hydroxyurea and mimosine from Sigma-
Aldrich (Cat: H8627 and M0253). Gemcitabine was a kind gift Dr.
William W. Bachovchin, Tufts University.
Western blotting and antibodies
LT proteins were detected using a mouse monoclonal antibody
from Santa Cruz Biotechnology that recognizes an epitope located
within residues 1–82 of the protein (Cat: sc-148). Flag-tagged E1 and
E2 proteins were detected using a mouse monoclonal antibody
from Sigma-Aldrich (M2-Flag antibody, Cat: F1804). β-tubulin wasdetected using a mouse monoclonal antibody from Sigma-Aldrich
(Cat: T0426). For Western blot analysis, proteins were transferred
onto polyvinylidene diﬂuoride membranes and detected using
horseradish peroxidase-conjugated sheep anti-mouse secondary
antibody from GE healthcare (Cat: NA931) and an enhanced
chemiluminescence detection kit (GE Healthcare).
Confocal ﬂuorescence microscopy
8×105 C33A cells were transfected with 500 ng of RFP-PCNA
expression plasmid (previously described in (Sporbert et al., 2005))
and grown on coverslips. Inhibitors were added 4 h post-transfection
and cells were ﬁxed 24 h later with 4% formaldehyde. Cells were
mounted using Vectashield mounting medium (Vector Laboratories).
Images were acquired using a LSM510 confocal laser coupled to an
Axiovert 100 M inverted scanning microscope (Zeiss, Toronto,
Canada) and analyzed using LSM Image Browser version 3.2.0.70
(Zeiss, Toronto, Canada).
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